Impact of stress and craving on return to cannabis use in postpartum women

Date Added
May 2nd, 2023
PRO Number
Pro00128029
Researcher
Constance Guille

List of Studies


Keywords
Drug Studies, Hormones, Non-interventional, Pregnancy, Substance Use, Women's Health
Summary

Cannabis is the most commonly used illicit substance among pregnant and postpartum women, with the postpartum period being a common time for relapse to cannabis. Currently there are no interventions for preventing return to cannabis use during this vulnerable time. The goal of this research is to better understand risk factors such as stress, craving, anxiety, mood, sleep, and hormone levels that may contribute to return to cannabis use during the postpartum period in order to help develop targeted prevention and treatment interventions in the future.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

Investigating the effect of the oral microbiome on cognition in HIV-infected chronic cannabis users

Date Added
February 9th, 2023
PRO Number
Pro00117243
Researcher
Wei Jiang

List of Studies


Keywords
Brain, Dental, HIV / AIDS, Memory Loss, Mental Health, Nervous System, Psychiatry, Substance Use
Summary

This study will examine how marijuana use can affect oral bacteria and brain health in people with HIV and without HIV. Early studies show that marijuana users have more oral bacteria than non-marijuana users. The increase in bacteria is believed to affect brain health. Participation in the study will be one visit. The visit will take approximately 120 minutes.

Institution
MUSC
Recruitment Contact
Wei Jiang
843-876-2457
jianw@musc.edu

A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study to Assess the Efficacy and Safety of Clavulanic Acid vs. Placebo for the Treatment of Cocaine Use Disorder

Date Added
December 19th, 2022
PRO Number
Pro00125021
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

This pilot study is to research whether or not the investigational drug clavulanic acid, along with medication management, can help people with cocaine use disorder who are interested in quitting. Participants who are eligible after screening visits are randomly assigned to take clavulanic acid or placebo for twelve weeks and will meet with study staff three times a week for urine drug screens.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

PCORI 1: Improving Maternal Mental Health & Substance Use Disorder Screening and Treatment

Date Added
November 1st, 2022
PRO Number
Pro00123833
Researcher
Constance Guille

List of Studies


Keywords
Depression, Mental Health, Obstetrics and Gynecology, Post Partum Depression, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The purpose of the study is to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online surveys. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Institution
MUSC
Recruitment Contact
Edie Douglas
843-792-5958
douglaed@musc.edu

PCORI 1: Improving Maternal Mental Health & Substance Use Disorder Screening and Treatment

Date Added
November 1st, 2022
PRO Number
Pro00123833
Researcher
Constance Guille

List of Studies


Keywords
Depression, Mental Health, Obstetrics and Gynecology, Post Partum Depression, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The purpose of the study is to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online surveys. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Institution
MUSC Health Florence Medical Center
Recruitment Contact
Edie Douglas
843-792-5958
douglaed@musc.edu

PCORI 1: Improving Maternal Mental Health & Substance Use Disorder Screening and Treatment

Date Added
November 1st, 2022
PRO Number
Pro00123833
Researcher
Constance Guille

List of Studies


Keywords
Depression, Mental Health, Obstetrics and Gynecology, Post Partum Depression, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The purpose of the study is to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online surveys. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Institution
MUSC Health Lancaster Medical Center
Recruitment Contact
Edie Douglas
843-792-5958
douglaed@musc.edu

A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Clinical Trial of Titrating Doses of Nabilone with Gabapentin for the Mitigation of Cannabis Withdrawal Symptoms

Date Added
September 14th, 2022
PRO Number
Pro00122680
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

This research study will include heavy, long-term cannabis users with moderate to severe use desire who want or need to discontinue cannabis use and have previously had symptoms of cannabis withdrawal. Subjects participating in this research study will receive either PP-01 higher dose or lower dose (combination of nabilone and gabapentin in a varied amount), nabilone only, gabapentin only or placebo (inactive substance). This study will assess whether the study drugs help to lessen or alleviate cannabis withdrawal symptoms in study subjects.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

Investigate B cell perturbations and immune reconstitution failure in response to antiretroviral therapy in HIV-infected cocaine users

Date Added
August 26th, 2022
PRO Number
Pro00119926
Researcher
Wei Jiang

List of Studies


Keywords
HIV / AIDS, Immune System, Substance Use
Summary

This proposed project is to investigate the role of cocaine use in B cell dysfunctions and poor immune recovery from antiretroviral therapy in HIV.

Institution
MUSC
Recruitment Contact
Wei Jiang
843-876-2457
jianw@musc.edu

Varenicline for treatment of e-cigarette dependence

Date Added
May 17th, 2022
PRO Number
Pro00120081
Researcher
Benjamin Toll

List of Studies


Keywords
Drug Studies, Substance Use
Summary

This is a smoking cessation study which is examining varenicline for use in reducing or quitting e-cigarettes. Half of the participants will receive a placebo pill and half will receive varenicline. All participants will be asked to complete weekly assessments and receive compensation for doing so.

Institution
MUSC
Recruitment Contact
Marian Chelsea Evangelista
8435097589
evangema@email.sc.edu

Evaluating Contributors to Relapse in Comorbid Major Depressive Disorder and Cannabis Use Disorder

Date Added
May 3rd, 2022
PRO Number
Pro00119957
Researcher
Erin Martin

List of Studies

Keywords
Depression, Substance Use
Summary

Both withdrawal symptoms and external stressors can contribute to relapse in people that are trying to quit using marijuana. These negative feelings may be more severe in people that also have Major Depressive Disorder, making it especially hard for them to quit. The purpose of this study is to examine differences in withdrawal symptoms and stress response in people with Cannabis Use Disorder that do or do not also have major depression. Study participation will involve 3 on-site laboratory visits over 6 days. Participants will be asked to not use marijuana for 3 of those days. Participants will complete mobile phone surveys multiple times each day, wear a watch to assess sleep quality, and provide blood samples for testing at each laboratory visit. At the final laboratory visit, participants will complete a stress task.

Institution
MUSC
Recruitment Contact
Erin Martin
843-876-3528
marterin@musc.edu



-- OR --